Oncology candidate returns to Lilly with $110m AurKa Pharma buy
Eli Lilly has announced plans to buy AurKa Pharma and its lead oncology compound AK-01, just days after purchasing the immuno-oncology firm Armo Biosciences.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs